OrthoPediatrics (NASDAQ:KIDS) Lifted to Hold at Zacks Investment Research

OrthoPediatrics (NASDAQ:KIDSGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Friday, Zacks.com reports.

According to Zacks, “OrthoPediatrics Corp. is a medical device company. It markets surgical systems for trauma and deformity, bone fractures and reconstruction procedures. OrthoPediatrics Corp. is based in NEW YORK. “

Other research analysts also recently issued research reports about the company. TheStreet downgraded OrthoPediatrics from a “c” rating to a “d+” rating in a research note on Thursday, May 5th. Truist Financial lowered their price objective on OrthoPediatrics from $70.00 to $54.00 in a research note on Friday, May 6th. Needham & Company LLC lowered their price objective on OrthoPediatrics from $83.00 to $65.00 and set a “buy” rating for the company in a research note on Thursday, March 3rd. Finally, Piper Sandler lowered their price objective on OrthoPediatrics from $80.00 to $55.00 in a research note on Thursday, May 5th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, OrthoPediatrics currently has an average rating of “Buy” and a consensus price target of $66.00.

Shares of KIDS stock traded up $1.85 on Friday, reaching $45.40. The company had a trading volume of 58,908 shares, compared to its average volume of 116,742. The stock has a market capitalization of $918.44 million, a PE ratio of -58.96 and a beta of 0.88. OrthoPediatrics has a one year low of $36.71 and a one year high of $73.91. The business’s 50-day moving average is $48.03 and its 200 day moving average is $52.27.

OrthoPediatrics (NASDAQ:KIDSGet Rating) last posted its earnings results on Wednesday, March 2nd. The company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.05. The firm had revenue of $24.81 million during the quarter, compared to analysts’ expectations of $24.78 million. OrthoPediatrics had a negative net margin of 14.98% and a negative return on equity of 7.04%. During the same quarter in the prior year, the business earned ($0.31) earnings per share. On average, sell-side analysts forecast that OrthoPediatrics will post -0.79 earnings per share for the current year.

In related news, General Counsel Daniel J. Gerritzen sold 3,918 shares of the company’s stock in a transaction on Wednesday, March 2nd. The stock was sold at an average price of $58.46, for a total value of $229,046.28. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Mark C. Throdahl sold 5,961 shares of the stock in a transaction on Wednesday, March 2nd. The stock was sold at an average price of $58.60, for a total value of $349,314.60. The disclosure for this sale can be found here. In the last quarter, insiders have sold 22,984 shares of company stock valued at $1,334,452. Corporate insiders own 30.30% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. UBS Group AG lifted its holdings in OrthoPediatrics by 106.4% in the third quarter. UBS Group AG now owns 421 shares of the company’s stock valued at $28,000 after acquiring an additional 217 shares during the period. Confluence Wealth Services Inc. purchased a new stake in OrthoPediatrics in the fourth quarter worth about $28,000. Point72 Hong Kong Ltd purchased a new stake in OrthoPediatrics in the first quarter worth about $26,000. Sageworth Trust Co of South Dakota purchased a new stake in OrthoPediatrics in the fourth quarter worth about $43,000. Finally, Maverick Capital Ltd. purchased a new stake in OrthoPediatrics in the third quarter worth about $73,000. 71.51% of the stock is currently owned by institutional investors.

OrthoPediatrics Company Profile (Get Rating)

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.

See Also

Get a free copy of the Zacks research report on OrthoPediatrics (KIDS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for OrthoPediatrics (NASDAQ:KIDS)

Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.